Investors navigate unprecedented midterm volatility as historical political patterns collide with stubborn inflation and fiscal gridlock.

Escalating jurisdictional disputes between federal officials and state attorneys general inject fresh policy uncertainty into financial markets ahead of the election.

Eli Lilly posted robust quarterly financial results driven by flagship injectables, though clinical nuances in its oral obesity pipeline tempered investor enthusiasm.

Gilead Sciences raised its annual product sales guidance following robust performance in its core HIV business, driven by strong Biktarvy demand and solid operational execution.

A legacy network of high-containment pathogen research facilities faces mounting operational strains, supply bottlenecks, and heightened international oversight.

Bristol Myers Squibb is defending its clinical pipeline after a patient death in an autoimmune trial, reassuring investors over its broader immunology strategy.

Investors navigate shifting margins and regulatory headwinds across healthcare equities as defensive capital rotates into high-conviction biopharma names.

Under CEO Tony Xu, DoorDash turned suburban expansion and rigorous unit economics into undisputed dominance across the US on-demand delivery sector.

Haleon shares slumped after the consumer healthcare giant trimmed its full-year guidance, driven by softening demand and shifting retail patterns in key markets.

Bristol Myers Squibb has raised its annual financial outlook following stronger-than-expected quarterly revenue, driven by robust uptake in its growth portfolio.

Eli Lilly posted significant revenue gains driven by unprecedented global demand for its blockbuster treatments Mounjaro and Zepbound, solidifying its leadership in the metabolic therapeutics market.

Merck posted robust top-line gains driven by enduring demand for blockbuster oncology drug Keytruda and rapid market adoption of newly launched Winrevair.